Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye Khoo, Richard J. Fitzgerald, Tom Fletcher, et al.
Journal of Antimicrobial Chemotherapy (2021) Vol. 76, Iss. 12, pp. 3286-3295
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Angélica Jayk Bernal, Monica Maria Gomes da Silva, Dany Badibanga Musungaie, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 6, pp. 509-520
Open Access | Times Cited: 1638
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Christopher Butler, Richard Hobbs, Oghenekome Gbinigie, et al.
The Lancet (2022) Vol. 401, Iss. 10373, pp. 281-293
Open Access | Times Cited: 316
Molnupiravir in COVID-19: A systematic review of literature
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2021) Vol. 15, Iss. 6, pp. 102329-102329
Open Access | Times Cited: 212
Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients
Dinah V. Parums
Medical Science Monitor (2022) Vol. 28
Open Access | Times Cited: 81
Molnupiravir: First Approval
Yahiya Y. Syed
Drugs (2022) Vol. 82, Iss. 4, pp. 455-460
Open Access | Times Cited: 77
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Ching‐Chi Lee, Chih‐Chia Hsieh, Wen‐Chien Ko
Antibiotics (2021) Vol. 10, Iss. 11, pp. 1294-1294
Open Access | Times Cited: 76
RdRp inhibitors and COVID-19: Is molnupiravir a good option?
Seyed Mohammad Reza Hashemian, Mohammad Hossein Pourhanifeh, Michael R. Hamblin, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112517-112517
Open Access | Times Cited: 70
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Saye Khoo, Richard J. Fitzgerald, Geoffrey Saunders, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 2, pp. 183-195
Open Access | Times Cited: 63
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—A narrative review
Sri Masyeni, Muhammad Iqhrammullah, Andri Frediansyah, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 3006-3016
Open Access | Times Cited: 62
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Review on molnupiravir as a promising oral drug for the treatment of COVID-19
Elham Zarenezhad, Mahrokh Marzi
Medicinal Chemistry Research (2022) Vol. 31, Iss. 2, pp. 232-243
Open Access | Times Cited: 49
Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis
Tyler Pitre, Rebecca Van Alstine, Genevieve Chick, et al.
Canadian Medical Association Journal (2022) Vol. 194, Iss. 28, pp. E969-E980
Open Access | Times Cited: 48
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective
Cecilia Pozzi, Anne Vanet, Valeria Francesconi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 3664-3702
Open Access | Times Cited: 26
Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
Ling Ye, Shicheng Fan, Pengfei Zhao, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 9, pp. 3598-3637
Open Access | Times Cited: 26
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges
Zhonglei Wang, Liyan Yang
Journal of Medical Virology (2021) Vol. 94, Iss. 4, pp. 1373-1390
Closed Access | Times Cited: 43
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
I’ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36
New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
Robert L. Atmar, Natalie Finch
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 8
Open Access | Times Cited: 34
Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience
Andrea De Vito, Agnese Colpani, Alessandra Bitti, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 11, pp. 5582-5588
Open Access | Times Cited: 33
How to use COVID-19 antiviral drugs in patients with chronic kidney disease
Ajinath Kale, Vishwadeep Shelke, Neha Dagar, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 20
Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis
Jakob J Malin, Stephanie Weibel, Henning Gruell, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 7, pp. 1586-1598
Open Access | Times Cited: 18
Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis
Chienhsiu Huang, Tsung-Lung Lu, Lichen Lin
Antibiotics (2023) Vol. 12, Iss. 2, pp. 393-393
Open Access | Times Cited: 17
Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
Ya Gao, Ming Liu, Zhifan Li, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 8, pp. 979-999
Open Access | Times Cited: 16
Ecofriendly bioanalytical validated RP-HPLC method for simultaneous determination of COVID-19 co-prescribed drugs employing quality by design and green chemistry
Sohair mohamed aboelghar, Maha A. Hegazy, Hebatallah A. Wagdy
Microchemical Journal (2024) Vol. 200, pp. 110292-110292
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top